Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

A large-scale analysis of targeted metabolomics data from heterogeneous biological samples provides insights into metabolite dynamics.

Lee HJ, Kremer DM, Sajjakulnukit P, Zhang L, Lyssiotis CA.

Metabolomics. 2019 Jul 9;15(7):103. doi: 10.1007/s11306-019-1564-8.

2.

Metabolic Regulation of Redox Balance in Cancer.

Purohit V, Simeone DM, Lyssiotis CA.

Cancers (Basel). 2019 Jul 8;11(7). pii: E955. doi: 10.3390/cancers11070955. Review.

3.

Auditory metabolomics, an approach to identify acute molecular effects of noise trauma.

Ji L, Lee HJ, Wan G, Wang GP, Zhang L, Sajjakulnukit P, Schacht J, Lyssiotis CA, Corfas G.

Sci Rep. 2019 Jun 25;9(1):9273. doi: 10.1038/s41598-019-45385-8.

4.

Hydrogen sulfide perturbs mitochondrial bioenergetics and triggers metabolic reprogramming in colon cells.

Libiad M, Vitvitsky V, Bostelaar T, Bak DW, Lee HJ, Sakamoto N, Fearon E, Lyssiotis CA, Weerapana E, Banerjee R.

J Biol Chem. 2019 Aug 9;294(32):12077-12090. doi: 10.1074/jbc.RA119.009442. Epub 2019 Jun 18.

PMID:
31213529
5.

Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis.

Li M, Chiang YL, Lyssiotis CA, Teater MR, Hong JY, Shen H, Wang L, Hu J, Jing H, Chen Z, Jain N, Duy C, Mistry SJ, Cerchietti L, Cross JR, Cantley LC, Green MR, Lin H, Melnick AM.

Cancer Cell. 2019 Jun 10;35(6):916-931.e9. doi: 10.1016/j.ccell.2019.05.002.

PMID:
31185214
6.

Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma.

Xu J, Reznik E, Lee HJ, Gundem G, Jonsson P, Sarungbam J, Bialik A, Sanchez-Vega F, Creighton CJ, Hoekstra J, Zhang L, Sajjakulnukit P, Kremer D, Tolstyka Z, Casuscelli J, Stirdivant S, Tang J, Schultz N, Jeng P, Dong Y, Su W, Cheng EH, Russo P, Coleman JA, Papaemmanuil E, Chen YB, Reuter VE, Sander C, Kennedy SR, Hsieh JJ, Lyssiotis CA, Tickoo SK, Hakimi AA.

Elife. 2019 Apr 1;8. pii: e38986. doi: 10.7554/eLife.38986.

7.

Enhanced oxidative phosphorylation in NKT cells is essential for their survival and function.

Kumar A, Pyaram K, Yarosz EL, Hong H, Lyssiotis CA, Giri S, Chang CH.

Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7439-7448. doi: 10.1073/pnas.1901376116. Epub 2019 Mar 25.

PMID:
30910955
8.

Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.

Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, Diehl JN, Goode GD, Chaika NV, Wang Y, Zhang GF, Witkiewicz AK, Knudsen ES, Petricoin EF 3rd, Singh PK, Macdonald JM, Tran NL, Lyssiotis CA, Ying H, Kimmelman AC, Cox AD, Der CJ.

Nat Med. 2019 Apr;25(4):628-640. doi: 10.1038/s41591-019-0368-8. Epub 2019 Mar 4.

9.

Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer.

Halbrook CJ, Pontious C, Kovalenko I, Lapienyte L, Dreyer S, Lee HJ, Thurston G, Zhang Y, Lazarus J, Sajjakulnukit P, Hong HS, Kremer DM, Nelson BS, Kemp S, Zhang L, Chang D, Biankin A, Shi J, Frankel TL, Crawford HC, Morton JP, Pasca di Magliano M, Lyssiotis CA.

Cell Metab. 2019 Jun 4;29(6):1390-1399.e6. doi: 10.1016/j.cmet.2019.02.001. Epub 2019 Feb 28.

PMID:
30827862
10.

IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.

Núñez FJ, Mendez FM, Kadiyala P, Alghamri MS, Savelieff MG, Garcia-Fabiani MB, Haase S, Koschmann C, Calinescu AA, Kamran N, Saxena M, Patel R, Carney S, Guo MZ, Edwards M, Ljungman M, Qin T, Sartor MA, Tagett R, Venneti S, Brosnan-Cashman J, Meeker A, Gorbunova V, Zhao L, Kremer DM, Zhang L, Lyssiotis CA, Jones L, Herting CJ, Ross JL, Hambardzumyan D, Hervey-Jumper S, Figueroa ME, Lowenstein PR, Castro MG.

Sci Transl Med. 2019 Feb 13;11(479). pii: eaaq1427. doi: 10.1126/scitranslmed.aaq1427.

11.

Ex vivo and in vivo stable isotope labelling of central carbon metabolism and related pathways with analysis by LC-MS/MS.

Yuan M, Kremer DM, Huang H, Breitkopf SB, Ben-Sahra I, Manning BD, Lyssiotis CA, Asara JM.

Nat Protoc. 2019 Feb;14(2):313-330. doi: 10.1038/s41596-018-0102-x.

PMID:
30683937
12.

Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis.

Santana-Codina N, Roeth AA, Zhang Y, Yang A, Mashadova O, Asara JM, Wang X, Bronson RT, Lyssiotis CA, Ying H, Kimmelman AC.

Nat Commun. 2018 Nov 23;9(1):4945. doi: 10.1038/s41467-018-07472-8.

13.

Biochemical Characterization and Structure-Based Mutational Analysis Provide Insight into the Binding and Mechanism of Action of Novel Aspartate Aminotransferase Inhibitors.

Holt MC, Assar Z, Beheshti Zavareh R, Lin L, Anglin J, Mashadova O, Haldar D, Mullarky E, Kremer DM, Cantley LC, Kimmelman AC, Stein AJ, Lairson LL, Lyssiotis CA.

Biochemistry. 2018 Nov 27;57(47):6604-6614. doi: 10.1021/acs.biochem.8b00914. Epub 2018 Nov 12.

PMID:
30365304
14.

New tricks for an old drug.

Nelson BS, Kremer DM, Lyssiotis CA.

Nat Chem Biol. 2018 Nov;14(11):990-991. doi: 10.1038/s41589-018-0137-x. No abstract available.

PMID:
30297874
15.

Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma.

Anglin J, Zavareh RB, Sander PN, Haldar D, Mullarky E, Cantley LC, Kimmelman AC, Lyssiotis CA, Lairson LL.

Bioorg Med Chem Lett. 2018 Sep 1;28(16):2675-2678. doi: 10.1016/j.bmcl.2018.04.061. Epub 2018 Apr 27.

16.

The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Abbruzzese JL, Andersen DK, Borrebaeck CAK, Chari ST, Costello E, Cruz-Monserrate Z, Eibl G, Engleman EG, Fisher WE, Habtezion A, Kim SK, Korc M, Logsdon C, Lyssiotis CA, Pandol SJ, Rustgi A, Wolfe BM, Zheng L, Powers AC.

Pancreas. 2018 May/Jun;47(5):516-525. doi: 10.1097/MPA.0000000000001037.

17.

Fine-Tuning Mitochondrial Dysfunction and Reductive Carboxylation.

Halbrook CJ, Nwosu ZC, Lyssiotis CA.

Trends Endocrinol Metab. 2018 Sep;29(9):599-602. doi: 10.1016/j.tem.2018.04.002. Epub 2018 Apr 23.

PMID:
29692332
18.

Menin regulates the serine biosynthetic pathway in Ewing sarcoma.

Svoboda LK, Teh SSK, Sud S, Kerk S, Zebolsky A, Treichel S, Thomas D, Halbrook CJ, Lee HJ, Kremer D, Zhang L, Klossowski S, Bankhead AR, Magnuson B, Ljungman M, Cierpicki T, Grembecka J, Lyssiotis CA, Lawlor ER.

J Pathol. 2018 Jul;245(3):324-336. doi: 10.1002/path.5085. Epub 2018 May 28.

19.

Tumor cross-talk networks promote growth and support immune evasion in pancreatic cancer.

Halbrook CJ, Pasca di Magliano M, Lyssiotis CA.

Am J Physiol Gastrointest Liver Physiol. 2018 Jul 1;315(1):G27-G35. doi: 10.1152/ajpgi.00416.2017. Epub 2018 Mar 15. Review.

20.

Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma.

Schofield HK, Zeller J, Espinoza C, Halbrook CJ, Del Vecchio A, Magnuson B, Fabo T, Daylan AEC, Kovalenko I, Lee HJ, Yan W, Feng Y, Karim SA, Kremer DM, Kumar-Sinha C, Lyssiotis CA, Ljungman M, Morton JP, Galbán S, Fearon ER, Pasca di Magliano M.

JCI Insight. 2018 Jan 25;3(2). pii: 97422. doi: 10.1172/jci.insight.97422. eCollection 2018 Jan 25.

21.

When Cancer Cells Are Given Lemo[NH3]s, They Make Lemo[NH3]ade.

Shan M, Lyssiotis CA.

Cell Metab. 2017 Dec 5;26(6):811-813. doi: 10.1016/j.cmet.2017.11.008.

22.

A vimentin binding small molecule leads to mitotic disruption in mesenchymal cancers.

Bollong MJ, Pietilä M, Pearson AD, Sarkar TR, Ahmad I, Soundararajan R, Lyssiotis CA, Mani SA, Schultz PG, Lairson LL.

Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9903-E9912. doi: 10.1073/pnas.1716009114. Epub 2017 Oct 30.

23.

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, King RJ, Abrego J, Goode GD, Dasgupta A, Illies AL, Gebregiworgis T, Dai B, Augustine JJ, Murthy D, Attri KS, Mashadova O, Grandgenett PM, Powers R, Ly QP, Lazenby AJ, Grem JL, Yu F, Matés JM, Asara JM, Kim JW, Hankins JH, Weekes C, Hollingsworth MA, Serkova NJ, Sasson AR, Fleming JB, Oliveto JM, Lyssiotis CA, Cantley LC, Berim L, Singh PK.

Cancer Cell. 2017 Sep 11;32(3):392. doi: 10.1016/j.ccell.2017.08.008. No abstract available.

24.

Metabolic Interactions in the Tumor Microenvironment.

Lyssiotis CA, Kimmelman AC.

Trends Cell Biol. 2017 Nov;27(11):863-875. doi: 10.1016/j.tcb.2017.06.003. Epub 2017 Jul 19. Review.

25.

Proteomic and Metabolomic Characterization of a Mammalian Cellular Transition from Quiescence to Proliferation.

Lee HJ, Jedrychowski MP, Vinayagam A, Wu N, Shyh-Chang N, Hu Y, Min-Wen C, Moore JK, Asara JM, Lyssiotis CA, Perrimon N, Gygi SP, Cantley LC, Kirschner MW.

Cell Rep. 2017 Jul 18;20(3):721-736. doi: 10.1016/j.celrep.2017.06.074.

26.

Emerging Roles for SIRT5 in Metabolism and Cancer.

Bringman-Rodenbarger LR, Guo AH, Lyssiotis CA, Lombard DB.

Antioxid Redox Signal. 2018 Mar 10;28(8):677-690. doi: 10.1089/ars.2017.7264. Epub 2017 Oct 26.

27.

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, King RJ, Abrego J, Goode GD, Dasgupta A, Illies AL, Gebregiworgis T, Dai B, Augustine JJ, Murthy D, Attri KS, Mashadova O, Grandgenett PM, Powers R, Ly QP, Lazenby AJ, Grem JL, Yu F, Matés JM, Asara JM, Kim JW, Hankins JH, Weekes C, Hollingsworth MA, Serkova NJ, Sasson AR, Fleming JB, Oliveto JM, Lyssiotis CA, Cantley LC, Berim L, Singh PK.

Cancer Cell. 2017 Jul 10;32(1):71-87.e7. doi: 10.1016/j.ccell.2017.06.004. Erratum in: Cancer Cell. 2017 Sep 11;32(3):392.

28.

Inhibiting Oxidative Phosphorylation In Vivo Restrains Th17 Effector Responses and Ameliorates Murine Colitis.

Franchi L, Monteleone I, Hao LY, Spahr MA, Zhao W, Liu X, Demock K, Kulkarni A, Lesch CA, Sanchez B, Carter L, Marafini I, Hu X, Mashadova O, Yuan M, Asara JM, Singh H, Lyssiotis CA, Monteleone G, Opipari AW, Glick GD.

J Immunol. 2017 Apr 1;198(7):2735-2746. doi: 10.4049/jimmunol.1600810. Epub 2017 Feb 27.

29.

Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer.

Halbrook CJ, Lyssiotis CA.

Cancer Cell. 2017 Jan 9;31(1):5-19. doi: 10.1016/j.ccell.2016.12.006. Review.

30.

Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis.

Wahl DR, Dresser J, Wilder-Romans K, Parsels JD, Zhao SG, Davis M, Zhao L, Kachman M, Wernisch S, Burant CF, Morgan MA, Feng FY, Speers C, Lyssiotis CA, Lawrence TS.

Cancer Res. 2017 Feb 15;77(4):960-970. doi: 10.1158/0008-5472.CAN-16-2008. Epub 2016 Dec 6.

31.

Erratum: Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion.

Sousa CM, Biancur DE, Wang X, Halbrook CJ, Sherman MH, Zhang L, Kremer D, Hwang RF, Witkiewicz AK, Ying H, Asara JM, Evans RM, Cantley LC, Lyssiotis CA, Kimmelman AC.

Nature. 2016 Dec 1;540(7631):150. doi: 10.1038/nature19851. Epub 2016 Oct 5. No abstract available.

PMID:
27706144
32.

Mitochondrial Amino Acid Metabolism Provides Vulnerabilities in Mutant KRAS-Driven Cancers.

Shah YM, Lyssiotis CA.

Gastroenterology. 2016 Nov;151(5):798-801. doi: 10.1053/j.gastro.2016.09.036. Epub 2016 Oct 3. No abstract available.

PMID:
27713037
33.

A novel small-molecule inhibitor of 3-phosphoglycerate dehydrogenase.

Mullarky E, Lairson LL, Cantley LC, Lyssiotis CA.

Mol Cell Oncol. 2016 Mar 30;3(4):e1164280. doi: 10.1080/23723556.2016.1164280. eCollection 2016 Jul.

34.

Adipocytes promote pancreatic cancer cell proliferation via glutamine transfer.

Meyer KA, Neeley CK, Baker NA, Washabaugh AR, Flesher CG, Nelson BS, Frankel TL, Lumeng CN, Lyssiotis CA, Wynn ML, Rhim AD, O'Rourke RW.

Biochem Biophys Rep. 2016 Sep;7:144-149. Epub 2016 Jun 7.

35.

Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer.

Lien EC, Lyssiotis CA, Cantley LC.

Recent Results Cancer Res. 2016;207:39-72. doi: 10.1007/978-3-319-42118-6_3. Review.

PMID:
27557534
36.

Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion.

Sousa CM, Biancur DE, Wang X, Halbrook CJ, Sherman MH, Zhang L, Kremer D, Hwang RF, Witkiewicz AK, Ying H, Asara JM, Evans RM, Cantley LC, Lyssiotis CA, Kimmelman AC.

Nature. 2016 Aug 25;536(7617):479-83. doi: 10.1038/nature19084. Epub 2016 Aug 10. Erratum in: Nature. 2016 Dec 1;540(7631):150.

37.

Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.

Juvekar A, Hu H, Yadegarynia S, Lyssiotis CA, Ullas S, Lien EC, Bellinger G, Son J, Hok RC, Seth P, Daly MB, Kim B, Scully R, Asara JM, Cantley LC, Wulf GM.

Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4338-47. doi: 10.1073/pnas.1522223113. Epub 2016 Jul 8.

38.

Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer.

Lien EC, Lyssiotis CA, Juvekar A, Hu H, Asara JM, Cantley LC, Toker A.

Nat Cell Biol. 2016 May;18(5):572-8. doi: 10.1038/ncb3341. Epub 2016 Apr 18.

39.

Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers.

Mullarky E, Lucki NC, Beheshti Zavareh R, Anglin JL, Gomes AP, Nicolay BN, Wong JC, Christen S, Takahashi H, Singh PK, Blenis J, Warren JD, Fendt SM, Asara JM, DeNicola GM, Lyssiotis CA, Lairson LL, Cantley LC.

Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1778-83. doi: 10.1073/pnas.1521548113. Epub 2016 Feb 1. Erratum in: Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):E1585.

40.

Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton.

Hu H, Juvekar A, Lyssiotis CA, Lien EC, Albeck JG, Oh D, Varma G, Hung YP, Ullas S, Lauring J, Seth P, Lundquist MR, Tolan DR, Grant AK, Needleman DJ, Asara JM, Cantley LC, Wulf GM.

Cell. 2016 Jan 28;164(3):433-46. doi: 10.1016/j.cell.2015.12.042.

41.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M.

Semin Cancer Biol. 2015 Dec;35 Suppl:S276-S304. doi: 10.1016/j.semcancer.2015.09.007. Review.

42.

Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone.

Chakrabarti G, Moore ZR, Luo X, Ilcheva M, Ali A, Padanad M, Zhou Y, Xie Y, Burma S, Scaglioni PP, Cantley LC, DeBerardinis RJ, Kimmelman AC, Lyssiotis CA, Boothman DA.

Cancer Metab. 2015 Oct 12;3:12. doi: 10.1186/s40170-015-0137-1. eCollection 2015.

43.

Dysregulated metabolism contributes to oncogenesis.

Hirschey MD, DeBerardinis RJ, Diehl AME, Drew JE, Frezza C, Green MF, Jones LW, Ko YH, Le A, Lea MA, Locasale JW, Longo VD, Lyssiotis CA, McDonnell E, Mehrmohamadi M, Michelotti G, Muralidhar V, Murphy MP, Pedersen PL, Poore B, Raffaghello L, Rathmell JC, Sivanand S, Vander Heiden MG, Wellen KE; Target Validation Team.

Semin Cancer Biol. 2015 Dec;35 Suppl:S129-S150. doi: 10.1016/j.semcancer.2015.10.002. Epub 2015 Oct 8. Review.

44.

A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.

Sadanandam A, Wullschleger S, Lyssiotis CA, Grötzinger C, Barbi S, Bersani S, Körner J, Wafy I, Mafficini A, Lawlor RT, Simbolo M, Asara JM, Bläker H, Cantley LC, Wiedenmann B, Scarpa A, Hanahan D.

Cancer Discov. 2015 Dec;5(12):1296-313. doi: 10.1158/2159-8290.CD-15-0068. Epub 2015 Oct 7.

45.

Triomics Analysis of Imatinib-Treated Myeloma Cells Connects Kinase Inhibition to RNA Processing and Decreased Lipid Biosynthesis.

Breitkopf SB, Yuan M, Helenius KP, Lyssiotis CA, Asara JM.

Anal Chem. 2015 Nov 3;87(21):10995-1006. doi: 10.1021/acs.analchem.5b03040. Epub 2015 Oct 12.

46.

Acetate fuels the cancer engine.

Lyssiotis CA, Cantley LC.

Cell. 2014 Dec 18;159(7):1492-4. doi: 10.1016/j.cell.2014.12.009. Erratum in: Cell. 2015 Jan 29;160(3):567.

47.

Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease.

Glick GD, Rossignol R, Lyssiotis CA, Wahl D, Lesch C, Sanchez B, Liu X, Hao LY, Taylor C, Hurd A, Ferrara JL, Tkachev V, Byersdorfer CA, Boros L, Opipari AW.

J Pharmacol Exp Ther. 2014 Nov;351(2):298-307. doi: 10.1124/jpet.114.218099. Epub 2014 Aug 14.

48.

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.

Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, Kost-Alimova M, Muller F, Colla S, Nezi L, Genovese G, Deem AK, Kapoor A, Yao W, Brunetto E, Kang Y, Yuan M, Asara JM, Wang YA, Heffernan TP, Kimmelman AC, Wang H, Fleming JB, Cantley LC, DePinho RA, Draetta GF.

Nature. 2014 Oct 30;514(7524):628-32. doi: 10.1038/nature13611. Epub 2014 Aug 10.

49.

Targeting metabolic scavenging in pancreatic cancer.

Lyssiotis CA, Cantley LC.

Clin Cancer Res. 2014 Jan 1;20(1):6-8. doi: 10.1158/1078-0432.CCR-13-2570. Epub 2013 Oct 28.

50.

Metabolic syndrome: F stands for fructose and fat.

Lyssiotis CA, Cantley LC.

Nature. 2013 Oct 10;502(7470):181-2. doi: 10.1038/502181a. No abstract available.

PMID:
24108049

Supplemental Content

Loading ...
Support Center